• MannKind and Rose Pharma partner on development of ROSE-010 Technosphere GLP-1 DPI for weight loss

  MannKind and Rose Pharma have announced a collaboration agreement that gives Rose a worldwide license for development of its ROSE-010 rapid-acting GLP-1 as an inhaled therapy for weight loss using MannKind’s Technosphere dry powder technology.… [Read more . . .]

• AirNexis announces results from Haisco’s Phase 2b trial of AN01 PDE3/4 inhibitor DPI in patients with COPD

  AirNexis Therapeutics has announced that a Chinese Phase 2b study of AN01 (HSK39004) PDE3/4 inhibitor DPI in COPD patients that was conducted by Haisco Pharmaceutical met its primary endpoint. AirNexis launched in early 2026 with… [Read more . . .]

• Rezubio initiates Phase 1 trial of RZ-520 inhaled therapy in development for the treatment of respiratory diseases

  Chinese biotech Rezubio has announced the initiation of a Phase 1 PK/PD study of RZ-520, which Rezubio describes as “a novel inhaled therapeutic drug candidate for the treatment of chronic respiratory diseases.” According to Rezubio,… [Read more . . .]

• FDA grants Fast Track designation to Liquidia’s Yutrepia treprostinil DPI for the treatment of Raynaud’s phenomenon in systemic sclerosis

  According to Liquidia, the FDA has granted Fast Track designation to the company’s Yutrepia inhaled dry powder treprostinil for the treatment of Raynaud’s phenomenon associated with systemic sclerosis (SSc-RP.). Yutrepia is currently approved in the… [Read more . . .]

• Chiesi announces European regulatory submissions for LGWP formulations of BDP/FF/GB and BDP/FF MDIs

  Chiesi has announced the acceptance of regulatory submissions for two LGWP versions of its metered dose inhalers that have been reformulated with Orbia‘s HFA 152a propellant. In the UK, the MHRA recently approved Chiesi’s HFA 152a Clenil Modulite beclometasone MDI for… [Read more . . .]

• Aptar announces that Nanopharm will provide development services for Aceso’s ACT-101 antisense oligonucleotide for CF

• Copley Scientific launches Inhalytix+ v2.0 and Critical Flow Controller TPK 200iX

• Chinese NMPA approves Milestone and Everest’s Cardamyst etripamil nasal spray for the treatment of PSVT

• Nemera launches DuoSpray bidose nasal delivery device for systemic drugs

• FDA accepts United Therapeutics’ sNDA to extend use of Tyvaso treprostinil inhalation solution for the treatment of IPF

More news . . .